Jul-Dec 2026 Catalysts for Mid-cap Pharma/Generics: Pharmaceuticals | Japan

Research evidence excerpt

Jul-Dec 2026 Catalysts for Mid-cap Pharma/Generics: Pharmaceuticals | Japan

IdeaCatalystMEvent Preview

Company / Catalyst Date Importance Surprise

Sumitomo Pharma 4506.T

Enzomenib (acute leukemia) Ph2 data 4Q26 High In-line

Takeaways:

• Ph2 monotherapy trial data for relapsed/refractory KMT2A is due in Oct-Dec 2026, and the firm plans

to file for FDA approval if the primary endpoint is met.

• We expect the readout at the American Society of Hematology (ASH) in Dec.

• Monotherapy Ph1/2 data showed results suggesting potential best-in-class efficacy versus

competitors. We expect a CR/CRh rate of 30–40% in Ph2.

• Readouts are also planned for Ph2 monotherapy trial data for relapsed/refractory NPM1 mutations in

Apr-Sep 2027 and Ph1/2 1L trial data of VEN/AZA vs. 7+3 regimen in Jul-Sep 2027.

Nuvisertib (myelofibrosis) Ph1/2 data 4Q26 High Modest upside surprise

• Ojjaara (Momelotinib) combination Ph1/2 trial data for relapsed/refractory patients is due in Oct-Dec

2026.

• The Ph1/2 trials showed an add-on effect from combined treatment with Ojjaara for relapsed/

refractory myelofibrosis

• Drug-drug interaction (DDI) with Jakafi (Ruxolitinib) is currently under evaluation, and we see the

possibility of a data readout for the Jakafi combination at the Dec ASH as well.

Dividend resumption 4Q26 Very High In-line

• We assume the earliest would be a resumption with 1H results. Dividends have been suspended since

the last one in F3/23.

• The firm has indicated a policy to resume dividends at the earliest possibility, and changed the

dividend plan for F3/26 4Q from the hitherto ‘no dividend’ to ‘undetermined’.

• F3/26 securities report states F3/27 core OP plan of ¥91bn assumes receipt of sales milestone on